Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 5, 2013

Novo Nordisk Funds Diabetes Fellowship Program at Oxford University

  • In a partnership that aims to support the career and scientific development of young researchers in the study and treatment of diabetes, Oxford University and Novo Nordisk will establish a number of postdoctoral fellowship opportunities. The program will be hosted by Oxford University and funded by Novo Nordisk.

    A total of 12 young researchers will be offered a three-year grant to support their research within the fields of diabetes, metabolism, and endocrinology. The goal is to support the development of a new generation of research leaders while further developing scientific excellence within diabetes, according to Novo Nordisk. The first four fellows in the program will start in fall 2014.

    "This new program will support the best young researchers doing novel work in the understanding of diabetes and its treatment,” said Hugh Watkins, professor of the Radcliffe Department of Medicine at Oxford University. “It is these early career researchers that will produce the new ideas, discoveries and advances that will improve diabetes treatment and care in the future.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »